Journals / Osteoporoz Dünyasından / 2004 / Cilt: 10 - Sayı: 4

The effect of alendronate in male osteoporosis

Erkek osteoporozunda alendronatın etkinliği

Pages
153–156
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In summary, alendronate increased lumbar spine and femoral bone mineral density, and was found to be an effective and well-tolerated drug in men with idiopathic osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoporosis in men is increasingly recognized as an important public health issue because of mortality and disability.
📊
Key Findings & Data:Approximately 25-30% of all hip fractures occur in men and men are over 3 times more likely to die following a hip fracture than women.
💡
Conclusion & Impact:In summary, alendronate increased lumbar spine and femoral bone mineral density, and was found to be an effective and well-tolerated drug in men with idiopathic osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Femur · Kemik yoğunluğu · Osteoporoz

Abstract

Osteoporosis in men is increasingly recognized as an important public health issue because of mortality and disability. Approximately 25-30% of all hip fractures occur in men and men are over 3 times more likely to die following a hip fracture than women. Nowadays, the importance of treatment in male osteoporosis is increasing. The aim of this study was to evaluate the effect of alendronate treatment on idiopathic male osteoporosis. Thirty-one male patients with idiopathic osteoporosis were enrolled in the study. The mean age was 63,32±10,26 . All patients were treated with Alendronate 10 mgr/daily and calcium 500 mgr/daily. Bone mineral density (BMD) was measured at baseline and at 1 and 2 years by using Dual Energy X Ray Absorbtiometry at the lumbar spine(L1-4 ) and proximal femur. There was a significant increase from baseline at lumbar spine and femoral BMD after 1 year and 2 years (p< 0,01). Lumbar spine BMD increased by 6% and 11% after 1 and 2 years respectively. Total femur BMD increased by 2.9% after 1 year and 5.1% after 2 years. No significant side effects occured during the study. In summary, alendronate increased lumbar spine and femoral bone mineral density, and was found to be an effective and well-tolerated drug in men with idiopathic osteoporosis.

Özet

Erkek osteoporozu neden olduğu morbidite ve disabilite nedeni ile günümüzde önemli bir sağlık sorunu olarak görülmektedir. Tüm kalça kırıklarının yaklaşık % 25-30’u erkeklerde görülmektedir ve bir kalça kırığı sonrasında ölüm oranı erkeklerde kadınlardan üç kat daha fazladır. Günümüzde erkeklerde de osteoporoz tedavisinin önemi giderek artmaktadır. Bu çalışmanın amacı idiopatik osteoporozu olan erkek hastalarda alendronat tedavisinin etkinliğinin değerlendirilmesidir. Çalışmaya idiopatik osteoporoz tanısı konan 31 erkek hasta alındı. Olguların yaş ortalaması 63,32±10,26 yıl idi. Tüm hastalar günlük 10 mgr Alendronat ve 500 mgr elementer kalsiyum ile tedavi edildi. Kemik mineral yoğunluğu Dual Energy X Ray absorbsiometri yöntemi kullanılarak başlangıçta, 1.yılda ve 2. yılda lomber bölge (L1-L4) ve proksimal femurdan ölçüldü. Lomber omurga ve femurda başlangıca göre 1. ve 2. yılda kemik mineral yoğunluğu değerlerinde istatistiksel anlamlı artış elde edildi(p<0,01).Kemik mineral yoğunluğu lomber bölgede 1. yılın sonunda %6 ve 2. yılın sonunda %11 oranında arttı. Total femurdaki artış 1. yılın sonunda %2.9 ve 2. yılın sonunda ise %5.1 oranında idi. Hastalarda ciddi bir yan etki gözlenmedi. Sonuç olarak bu çalışmada Alendronat lomber bölge ve femurda kemik mineral yoğunluğunda artış sağlamış ve idiopatik erkek osteoporozu olan erkek hastaların tedavisinde etkin ve tolere edilebilen bir tedavi seçeneği olarak bulunmuştur

🔖

Cite This Article

EL, Ö., BİRCAN, Ç., ŞAHİN, E., ADALMAZ, B., PEHLİVAN, K. E., KIZIL, R., ŞENOCAK, Ö., PEKER, Ö., ÖNCEL, S. (2004). The effect of alendronate in male osteoporosis. Osteoporoz Dünyasından, Cilt: 10 - Sayı: 4, 153–156. https://ajindex.com/articles/286842

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Seeman E.Osteoporosis in men. Osteoporos Int(Suppl) 1999;2:97-110
  2. Melton III LJ. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001;69:179-181
  3. Orwoll ES. Osteoporosis in men.Osteoporos Int 1998;27:349-367
  4. Center JR, Nyugen TU, Schneider D, Sambrook PN, et al. Mortality after major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882
  5. Orwoll ES. Clinician’s Manual on Male Osteoporosis. Science Press, London, 2001
  6. Ringe JD, Orwoll E, Daifotis A, Lombardini A. Treatment of male osteoporosis: Recent advances with alendronate. Osteoporos Int 2002;13:195-199
  7. Cummings SR, Black DM, Nevitt MC, Browner W, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75
  8. Nevitt MC, Johnell O, Black DM, Ensrud K, et al. Bone mineral density predicts non-spine fractures in very elderly women. Osteoporos Int 1994; 4:325-331
  9. Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon WM,et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-1923
  10. De Laet CEDH, Van Hout BA, Burger H, Weel AEAM, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-1593
  11. Orwoll E, Ettinger M, Weiss S, Miller P, et al. Alendronate for treatment of osteoporosis in men. N Engl J Med 2000;343:604-610
  12. Ho YV, Frauman AG, Thompson W, Seeman E. Effects of Alendronate on bone denstiy in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101
  13. Weber TJ, Drezner MK. Effect of alendronate treatment on bone mineral density in male idiopathic osteoporosis. Metabolism 2001;50:912-915
  14. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5255
  15. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, et al. Alendronate treatment in men with primary osteoporosis: A three year longitudinal study. Calcif Tissue Int 2003;73:133-139
  16. Liberman UA, Weiss SR, Broll J, Mine HW, et al. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443
  17. Cummings SR, Black DM, Thompson DE, Applegate WB, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from Fracture Intervention Trial. JAMA 1998;280:2077